Loading clinical trials...
Loading clinical trials...
A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies
Conditions
Interventions
NIS793
PDR001
Locations
12
United States
Sarah Cannon Research Institute SC
Nashville, Tennessee, United States
Huntsman Cancer Institute SC
Salt Lake City, Utah, United States
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Würzburg, Germany
Start Date
April 25, 2017
Primary Completion Date
June 18, 2021
Completion Date
June 18, 2021
Last Updated
January 31, 2022
NCT05468034
NCT04541381
NCT07177937
NCT03137095
NCT06043817
NCT05671510
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions